Gene Regulation Publications & Patents

Gene Regulation Publications & Patents - Research at Peter Mac

Recent Publications

Gough, D.J.,, Sabapathy, K., Ko, Y-N, E., Arthur, H.A., Schreiber, R.D., Trapani, J.A., Clarke, C.J.P., Johnstone, R.W. A novel C-Jun-dependent signal transduction pathway necessary for the transcriptional activation of IFNgamma -response genes. 2007 J. Biol. Chem. 282(2):938-946 [<,5.6]

Kaufmann, T., Tai, L, Ekert, P.G., Huang, D.C.S., Norris, F., Lindemann, R.K., Johnstone, R.W., Dixit, V.M. and Strasser, A. The Pro-Apoptotic BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell Cycle Arrest. 2007 Cell 129(2):423-33. [<,29.9]

Rasheed, W.K., Johnstone, R.W. and Prince, H.M. Histone Deacetylase Inhibitors in Cancer Therapy: Clinical Review. 2007 Expert Opinion on Investigational Drugs16(5): 659-78. [27,3.7]

Lindemann, R.K., A. Newbold, A., Whitecross, K.F., Cluse, L.A., Frew, A.J., Ellis, L., Williams S., Wiegmans, A., Dear, A.E., Scott, C.L., Pelligrini, M.. Wei, A., Marks, P.A., Richon, V.M., Lowe, S.W., Smyth, M.J., and Johnstone, R.W. Mechanistic analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors using a genetically tractable mouse model of B cell lymphoma. 2007 Proc. Natl. Acad. Sci. USA 104, 8071–8076 [<,9.6]
[This paper was featured in the “Research Highlights” section of Nature Reviews Cancer 7, 403 (June 2007)]

Kaufmann T, Tai L, Ekert P.G, Huang D.C, Norris F, Lindemann R.K, Johnstone R.W, Dixit V.M, Arnoult D, Strasser A. Response: does bid play a role in the DNA damage response? Cell. 2007 Jul 13;130(1):10-1. [<,29.9]

Ludlow L.E., Hii L.L., Thorpe J., Newbold A., Tainton K.M., Trapani J.A., Clarke C.J.P., Johnstone R.W. Cloning and characterisation of IFI206 : A new murine HIN-200 family member. J. Cell Biochem. 2008 103(4):1270-82 [<,3.4]

Bishton M, Kenealy M, Johnstone R.W., Rasheed W, Prince HM. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents. Expert Rev. Anticancer Ther. 2007 Oct;7(10):1439-49.

Stagg, J., Johnstone, R.W., Smyth, M.J. From cancer immunosurveillance to cancer immunotherapy. Immunological Reviews 2007 220(1):82-101. [<, 10.8]

Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
Proc Natl Acad Sci U S A. 2007 104(49):19512-7. [<,9.6]

Sedelies K.A., Ciccone A., Sutton V.R., Clarke C.J.P., Oliaro J., Scott F.L., Silke J., Green D.R., Johnstone R.W., Bird P.I., Trapani J.A. and Waterhouse N.J. Blocking granule mediated death by primary human NK cells requires both protection of mitochondria and inhibition of caspase activity. 2008 Cell Death and Diff. 15(4):708-17 [<,8.3]

Newbold, A., Lindemann, R.K., Cluse, L.A., Whitecross, K.F., Dear, A.E., Johnstone, R.W. Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor Romidepsin. 2008. Mol. Can. Ther. 7(5):1066-79. [<, 5.1]

Ellis, L., Pan, Y., Smyth, G.K., George, D.J., McCormcak, C., Williams-Traux, R.,
Mita, M., Beck, J., Ryan, G., Atadja, P., Butterfoss, D., Dugan, M., Culver, K., Prince, H.M*, Johnstone, R.W*. The histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T cell lymphoma. 2008. Clin.Cancer Res. 14, 4500-4510 [<, 6.2]. (* Note co-senior and corresponding authors)

Ludlow1 L.E., Purton L.E., Klarmann K, Gough D.J., Hii L,L., Trapani J.A., Keller J.R., Clarke C.J.P., Johnstone R.W. The role of p202 on regulating hematopoietic cell proliferation and differentiation. 2008 J. Interferon Cytokine Res. 28(1):5-11. [<, 2.67]

Rasheed, W.K., Bishton, M., Johnstone, R.W. and Prince, H.M. Histone Deacetylase Inhibitors in lymphoma and solid malignancies. 2008 Expert Review in Anticancer Therapy. 8(3):413-32. [<, 4.05]

Frew, A.J., Lindemann, R.K., Martin, B.P., Clarke, C.J.P., Sharkey, J., Anthony, D.A., Banks, K-M., Haynes, N.M., Gangatirkir1, Stanley, P.K., Bolden, J.E., Takeda, K., Yagita, H., Secrist, J.P., Mark. J. Smyth, M.J., Johnstone, R.W. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. 2008 Proc Natl Acad Sci U S A. 105(32):11317-22. [<,9.6]
This paper was featured in the “Research Highlights” section of Nature Reviews Drug Discovery

Stagg, J, Sharkey, J., Pommey, S., Young, R., Takeda, K., Yagita, H., Johnstone, R.W., Smyth, M.J. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an anti-tumor immune response. 2008 Proc Natl Acad Sci U S A. 105(42):16254-9. [<,9.6]

Johnstone, R.W., Frew, A.J., Smyth, M.J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nature Reviews Cancer 2008 8(10): 782-798. [<, 31.6]

Gough, D.J., Levy, D.E., Johnstone, R.W., Clarke, C.J.P. IFN signaling – Does it mean JAK-STAT? Cytokine Growth Factor Reviews 2008 19(5-6):383-94. [<,11.8]

Peart, M.J. and Johnstone. R.W. Epigenetic Drugs – Histone Deacetylase Inhibitors. In : “Epigenetics in Biology and Medicine. “ 1st Edition (Manel Esteller Editor) pp 49-72. CRC Press, Boca Raton, FL, USA

Whitecross, K.F., Alsop, A.E., Cluse, L.A., Wiegmans, A., Banks, K.M., Coomans, C., Peart, M.J., Newbold, A., Lindemann, R.K., Johnstone, R.W. Defining the target specificity of ABT-737 and synergistic anti-tumor activities in combination with histone deacetylase inhibitors. 2009 Blood 113(9):1982-91 [<,10.9].

Bolitho, P, Street, S.E.A., Westwood, J.A., Edelmann, W., MacGregor, D., Waring, P., Murray, W.K., Godfrey, D.I., Trapani, J.A., Johnstone, R.W., Smyth, M.J. Perforin-mediated suppression of B cell lymphoma. 2009 Proc Natl Acad Sci U S A. 106(8):2723-8.. [<,9.6]

Bolden, J.E., Johnstone, R.W., Frew, A.J. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. 2009 Cancer Letters 280(2):125-33. [<, 3.4].

Algar EM, Muscat A, Dagar V, Rickert C, Chow CW, Biegel JA, Ekert PG, Saffery R, Craig J, Johnstone RW, Ashley DM. Imprinted CDKN1C Is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. 2009 PLoS ONE. 2009;4(2):e4482

Ellis L, Bots M, Lindemann RK, Bolden JE, Newbold A, Cluse LA, Scott CL, Strasser A, Atadja P, Lowe SW, Johnstone R.W. The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy. 2009 Blood (In press).

Bots M. and Johnstone RW. Rational combinations using HDAC inhibitors. 2009 Clin. Cancer Res. 2009 15(12):3970-7

Ellis L., Atadja PW and Johnstone RW. Epigenetics in Cancer: Targeting Chromatin Modifications. 2009 Molecular Cancer Therapeutics 2009 8(6):1409-20.

Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009 Jun;5(5):601-12.

Patents

Patent No. - 60/137933
Year taken out – 1999
Inventors – Dr Ricky W. Johnstone, Dr Mark M. Smyth
Assignee – The Austin Research Institute
Title – Cells for identifying potential therapeutics.

Patent No. – PQ5528
Year taken out – 2000
Inventors – Dr Ricky W. Johnstone, Dr Joseph A. Trapani
Assignee – The Austin Research Institute
Title – Promoters and regulators thereof.

Patent No. PR7167
Year taken out – 2001
Inventors – Dr Ricky W. Johnstone, Dr Mark M. Smyth
Assignee – The Peter MacCallum Cancer Institute
Title – Methods of inducing cell death and methods of treatment.

Patent No. PCT/AU01/01635
Year taken out – 2001
Inventors – Dr Andreas Suhrbier, Mr Grant Darnell, Dr Ricky W. Johnstone
Assignee – Queensland Institute of Medical Research
Title – Rb-binding protein.

Patent No. 61/108,319
Year taken out – 2008
Inventors –Dr Mitchell Keegan, Dr Ricky W. Johnstone, Ms Leonie Cluse, Ms Andrea Newbold
Assignee – Gloucester Pharmaceuticals
Title – Cancer Therapy